Pharmaceutical Technology3 小时
Mosliciguat by Bayer for Kidney Disease (Nephropathy): Likelihood of Approval
Mosliciguat is under clinical development by Bayer and currently in Phase I for Kidney Disease (Nephropathy). According to GlobalData, Phase I drugs for Kidney Disease (Nephropathy) have a 71% phase ...
Pharmaceutical Technology4 小时
Treprostinil by United Therapeutics for Idiopathic Pulmonary Fibrosis: Likelihood of Approval
Treprostinil is under clinical development by United Therapeutics and currently in Phase III for Idiopathic Pulmonary Fibrosis.
pulmonologyadvisor8 小时
CTEPH Predictors Following Pulmonary Embolism
In the era of DOACs, risk for CTEPH following pulmonary embolism is affected by multiple factors, including gender and heart load.